Recommendation of the President – Apixaban Adamed (apixaban)
On 24 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 39/2026 on the inclusion of the medicinal product Apixaban Adamed (apixaban) in the reimbursement program for the following indication: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one risk factor, such as a history of stroke or transient ischemic attack; age ≥75 years; hypertension; diabetes; symptomatic heart failure (NYHA class ≥II)